Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samer Al Hadidi

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Haematologica|August 30, 2023
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myelomaLindsay Hammons, Aniko Szabo, Abhishek Janardan, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
Blood Cancer Journal|November 6, 2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stagesYan Cheng, Fumou Sun, Daisy V Alapat, et al.
Blood Cancer Journal|April 23, 2025
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myelomaMeera Mohan, Aniko Szabo, Heloise Cheruvalath, et al.
Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.
Cancers|March 28, 2024
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell TransplantationWancheng Guo, Christopher Strouse, David Mery, et al.
Bone Marrow Transplantation|February 16, 2024
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myelomaMeera Mohan, Aniko Szabo, Anannya Patwari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2026
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1Rahul Banerjee, Matthew C Cheung, Benjamin Derman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Nature Communications|January 19, 2024
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growthFumou Sun, Yan Cheng, Visanu Wanchai, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Haematologica|August 30, 2023
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myelomaLindsay Hammons, Aniko Szabo, Abhishek Janardan, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
Blood Cancer Journal|November 6, 2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stagesYan Cheng, Fumou Sun, Daisy V Alapat, et al.
Blood Cancer Journal|April 23, 2025
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myelomaMeera Mohan, Aniko Szabo, Heloise Cheruvalath, et al.
Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.
Cancers|March 28, 2024
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell TransplantationWancheng Guo, Christopher Strouse, David Mery, et al.
Bone Marrow Transplantation|February 16, 2024
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myelomaMeera Mohan, Aniko Szabo, Anannya Patwari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2026
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1Rahul Banerjee, Matthew C Cheung, Benjamin Derman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Nature Communications|January 19, 2024
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growthFumou Sun, Yan Cheng, Visanu Wanchai, et al.
Pageof 10